An miR-502–Binding Site Single-Nucleotide Polymorphism in the 3′-Untranslated Region of the SET8 Gene Is Associated with Early Age of Breast Cancer Onset

Purpose: MicroRNAs regulate gene expression by binding to the 3′-untranslated region (UTR) of target genes. Single-nucleotide polymorphisms of critical genes may affect their regulation by microRNAs. We have identified a single-nucleotide polymorphism within the miR-502 seed binding region in the 3′-UTR of the SET8 gene. SET8 methylates TP53 and regulates genome stability. We investigated the role of this SET8 single-nucleotide polymorphism and in concert with the TP53 codon 72 single-nucleotide polymorphism in the propensity for onset of breast cancer. Experimental Design: We measured the SET8 single-nucleotide polymorphisms in a case-control study on 1,110 breast cancer cases and 1,097 controls. Results: The SET8 CC and TP53 GG genotypes were independently associated with an earlier age of breast cancer onset in an allele-dose-dependent manner (for SET8, 52.2 years for TT, 51.4 for TC, and 49.5 for CC; and for TP53, 53.1 years for CC, 51.5 for GC, 50.7 for GG). Individuals with combined SET8 CC and TP53 GG genotypes developed cancer at a median age of 47.7 years as compared with 54.6 years for individuals with combined SET8 TT and TP53 CC genotypes. In the 51 breast cancer tissue samples tested, the SET8 CC genotype was associated with reduced SET8, but not miR-502, transcript levels. Conclusions: These data suggest that the miR-502–binding site single-nucleotide polymorphism in the 3′-UTR of SET8 modulates SET8 expression and contributes to the early development of breast cancer, either independently or together with the TP53 codon 72 single-nucleotide polymorphism. Larger studies with multiethnic groups are warranted to validate our findings. (Clin Cancer Res 2009;15(19):6292–300)

[1]  Paul Tempst,et al.  Regulation of p53 activity through lysine methylation , 2004, Nature.

[2]  D. Malkin,et al.  Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. , 2007, Cancer research.

[3]  G. Zhu,et al.  SET8 plays a role in controlling G1/S transition by blocking lysine acetylation in histone through binding to H4 N-terminal tail , 2008, Cell cycle.

[4]  A. Børresen-Dale,et al.  TP53 mutations in synchronous and metachronous bilateral breast carcinomas. , 2008, Cancer genetics and cytogenetics.

[5]  H. Meijers-Heijboer,et al.  Two TP53 germline mutations in a classical Li-Fraumeni syndrome family , 2007, Familial Cancer.

[6]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[7]  G. Zhu,et al.  SET8 Recognizes the Sequence RHRK20VLRDN within the N Terminus of Histone H4 and Mono-methylates Lysine 20* , 2005, Journal of Biological Chemistry.

[8]  T. Crook,et al.  The p53 pathway in breast cancer , 2002, Breast Cancer Research.

[9]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[10]  K. McManus,et al.  Catalytic Function of the PR-Set7 Histone H4 Lysine 20 Monomethyltransferase Is Essential for Mitotic Entry and Genomic Stability* , 2008, Journal of Biological Chemistry.

[11]  Michael Kertesz,et al.  The role of site accessibility in microRNA target recognition , 2007, Nature Genetics.

[12]  V. Scaria,et al.  MicroRNA-mediated up-regulation of an alternatively polyadenylated variant of the mouse cytoplasmic β-actin gene , 2008, Nucleic acids research.

[13]  S. Hussain,et al.  p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis. , 2006, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[14]  Jian-Fu Chen,et al.  The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation , 2006, Nature Genetics.

[15]  Alexei Vazquez,et al.  The genetics of the p53 pathway, apoptosis and cancer therapy , 2008, Nature Reviews Drug Discovery.

[16]  Hengbin Wang,et al.  Purification and Functional Characterization of SET8, a Nucleosomal Histone H4-Lysine 20-Specific Methyltransferase , 2002, Current Biology.

[17]  Shuomin Zhu,et al.  MicroRNA-21 targets tumor suppressor genes in invasion and metastasis , 2008, Cell Research.

[18]  T. Dalmay,et al.  The cartilage specific microRNA‐140 targets histone deacetylase 4 in mouse cells , 2006, FEBS letters.

[19]  K. Hemminki,et al.  Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. , 2007, Carcinogenesis.

[20]  K. Darvishi,et al.  Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism , 2007, Breast Cancer Research.

[21]  A. Mills,et al.  p53: at the crossroad between cancer and ageing , 2007, The Journal of pathology.

[22]  Wei Zhang,et al.  Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. , 2007, Carcinogenesis.

[23]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[24]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[25]  F. Slack,et al.  A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. , 2008, Cancer research.

[26]  Jian Gu,et al.  Single Nucleotide Polymorphisms of microRNA Machinery Genes Modify the Risk of Renal Cell Carcinoma , 2008, Clinical Cancer Research.

[27]  Or Gozani,et al.  Modulation of p53 function by SET8-mediated methylation at lysine 382. , 2007, Molecular cell.

[28]  R. Catarino,et al.  TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. , 2005, Cancer genetics and cytogenetics.

[29]  Z. Shao,et al.  MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. , 2008, Carcinogenesis.

[30]  Robert Johansson,et al.  Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. , 2008, Carcinogenesis.

[31]  Angélica Rangel-López,et al.  Variaciones genéticas del gen supresor de tumores TP53: relevancia y estrategias de análisis , 2006 .

[32]  Hongbing Shen,et al.  Genetic variants of miRNA sequences and non-small cell lung cancer survival. , 2008, The Journal of clinical investigation.

[33]  Gaofeng Wang,et al.  Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. , 2008, American journal of human genetics.

[34]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[36]  David J. Hunter,et al.  The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses’ health studies , 2006, Cancer Causes & Control.

[37]  Joseph S Brunzelle,et al.  Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. , 2005, Genes & development.

[38]  A. Levine,et al.  Single-nucleotide polymorphisms in the p53 pathway. , 2005, Cold Spring Harbor symposia on quantitative biology.

[39]  Guy Leclercq,et al.  p53 and breast cancer, an update. , 2006, Endocrine-related cancer.

[40]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[41]  Junjie Chen,et al.  Direct Interaction between SET8 and Proliferating Cell Nuclear Antigen Couples H4-K20 Methylation with DNA Replication* , 2008, Journal of Biological Chemistry.

[42]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[43]  Edwin Wang,et al.  Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers , 2007, Nucleic acids research.

[44]  K. Helin,et al.  The histone methyltransferase SET8 is required for S-phase progression , 2007, The Journal of cell biology.

[45]  Yu-Ping Yang,et al.  The p53-dependent apoptotic pathway of breast cancer cells (BC-M1) induced by the bis-type bioreductive compound aziridinylnaphthoquinone , 2004, Breast Cancer Research.

[46]  F. Tsai,et al.  p53 codon 72 proline/arginine polymorphism and autoimmune thyroid diseases , 2008, Journal of clinical laboratory analysis.

[47]  Tom Walsh,et al.  Ten genes for inherited breast cancer. , 2007, Cancer cell.

[48]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[49]  Hua Zhao,et al.  A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. , 2008, Carcinogenesis.